International Centre for Circulatory Health, NHLI, St. Mary's Hospital and Imperial College London, St. Mary'sCampus, London, United Kingdom.
J Am Coll Cardiol. 2010 Apr 27;55(17):1875-81. doi: 10.1016/j.jacc.2009.11.084.
We hypothesized that an amlodipine-based regimen would have more favorable effects on left ventricular (LV) diastolic function.
Different antihypertensive therapies may vary in their effect on LV diastolic function.
The HACVD (Hypertension Associated Cardiovascular Disease) substudy of ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) collected detailed cardiovascular phenotypic data on a subset of 1,006 participants recruited from 2 centers (St. Mary's Hospital, London, and Beaumont Hospital, Dublin). Conventional and tissue Doppler echocardiography and measurement of plasma B-type natriuretic peptide (BNP) were performed approximately 1 year after randomization to atenolol-based or amlodipine-based antihypertensive treatment to assess LV diastolic function.
On-treatment blood pressure (BP) (mean +/- SD) was similar in both groups: atenolol-based regimen, systolic BP of 137 +/- 17 mm Hg, diastolic BP of 82 +/- 9 mm Hg; amlodipine-based regimen, systolic BP of 136 +/- 15 mm Hg, diastolic BP of 80 +/- 9 mm Hg. Ejection fraction did not differ between groups, but early diastolic mitral annular velocity (E'), a measure of diastolic relaxation, was lower in patients on the atenolol-based regimen: atenolol-based regimen, 7.9 +/- 1.8; amlodipine-based regimen, 8.8 +/- 2.0. A measure of left ventricular filling pressure, E/E', and BNP were significantly higher in patients on the atenolol-based regimen. Differences in E', E/E', and BNP remained significant after adjustment for age and sex. Further adjustment for systolic BP, LV mass index, and heart rate had no impact on differences in mean E' or BNP. The difference in E/E' was attenuated.
Patients receiving treatment with an amlodipine-based regimen had better diastolic function than patients treated with the atenolol-based regimen. Treatment-related differences in diastolic function were independent of BP reduction and other factors that are known to affect diastolic function.
我们假设氨氯地平为基础的治疗方案对左心室(LV)舒张功能有更有利的影响。
不同的降压治疗方法对 LV 舒张功能的影响可能不同。
ASCOT(盎格鲁-斯堪的纳维亚心脏结局试验)的 HACVD(高血压相关心血管疾病)子研究在从 2 个中心(伦敦圣玛丽医院和都柏林博蒙特医院)招募的 1006 名参与者的子集中收集了详细的心血管表型数据。在随机分配到以阿替洛尔为基础或氨氯地平为基础的降压治疗后大约 1 年,进行常规和组织多普勒超声心动图检查,并测量血浆 B 型利钠肽(BNP),以评估 LV 舒张功能。
两组治疗中的血压(BP)(均值 +/- SD)相似:以阿替洛尔为基础的方案,收缩压为 137 +/- 17mmHg,舒张压为 82 +/- 9mmHg;以氨氯地平为基础的方案,收缩压为 136 +/- 15mmHg,舒张压为 80 +/- 9mmHg。两组间射血分数无差异,但舒张早期二尖瓣环速度(E'),即舒张松弛的指标,在接受阿替洛尔为基础方案的患者中较低:阿替洛尔为基础的方案,7.9 +/- 1.8;以氨氯地平为基础的方案,8.8 +/- 2.0。以阿替洛尔为基础的方案患者的左心室充盈压指标 E/E'和 BNP 明显升高。调整年龄和性别后,E'、E/E'和 BNP 的差异仍然显著。进一步调整收缩压、左心室质量指数和心率对平均 E'或 BNP 差异没有影响。E/E'的差异减弱。
接受氨氯地平为基础的治疗方案的患者舒张功能优于接受阿替洛尔为基础的治疗方案的患者。舒张功能的治疗相关差异独立于血压降低和其他已知影响舒张功能的因素。